Asciminib: an investigational agent for the treatment of chronic myeloid leukemia

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety2019 · 142 citations
2. 2Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial2020 · 53 citations
3. 3How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)2020 · 42 citations